2024
Mechanisms of therapeutic change after psychedelic treatment in OCD
Maloney G, Ching T, Kichuk S, Pittenger C, Kelmendi B. Mechanisms of therapeutic change after psychedelic treatment in OCD. Psychiatry Research 2024, 336: 115907. PMID: 38615521, PMCID: PMC11190873, DOI: 10.1016/j.psychres.2024.115907.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderMechanisms of therapeutic changeAversive eventsImagery rescriptingPsychedelic treatmentPsychotherapeutic treatmentPsychotherapeutic frameworkSymptom reductionTherapeutic changePsychotherapyNegative emotionsPsychological mechanismsCore beliefsPilot dataNovel treatmentRescriptingEmotionsDisordersSymptomsReprocessingTreatmentBeliefsResistance to first-lineIndividualsIntervention
2023
Pilot study suggests DNA methylation of the glucocorticoid receptor gene (NR3C1) is associated with MDMA-assisted therapy treatment response for severe PTSD
Lewis C, Tafur J, Spencer S, Green J, Harrison C, Kelmendi B, Rabin D, Yehuda R, Yazar-Klosinski B, Cahn B. Pilot study suggests DNA methylation of the glucocorticoid receptor gene (NR3C1) is associated with MDMA-assisted therapy treatment response for severe PTSD. Frontiers In Psychiatry 2023, 14: 959590. PMID: 36815187, PMCID: PMC9939628, DOI: 10.3389/fpsyt.2023.959590.Peer-Reviewed Original ResearchPost-traumatic stress disorderSevere post-traumatic stress disorderTreatment responseClinical trialsRecent phase 3 clinical trialsPhase 3 clinical trialsClinician-Administered PTSD ScaleParent clinical trialKey HPA axis genesHPA axis genesPTSD symptom improvementGlucocorticoid receptor geneFalse discovery rate correctionAdrenal genesPlacebo groupSymptom improvementLarge cohortMethylation changesEpigenetic changesSymptom reductionPTSD ScaleTherapyHPA genesStress disorderPilot study